Page last updated: 2024-08-23

tobramycin and zithromax

tobramycin has been researched along with zithromax in 59 studies

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.69)	18.2507
2000's	18 (30.51)	29.6817
2010's	30 (50.85)	24.3611
2020's	10 (16.95)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Duewelhenke, N; Eysel, P; Krut, O	1
Lombardo, F; Obach, RS; Waters, NJ	1
Alba, V; Blasco, MD; Espinal, P; Fernández-Cuenca, F; Marti, S; Pascual, A; Ruiz, M; Sánchez-Céspedes, J; Vila, J	1
Esteban, J; Fernández-Martínez, AI; Fernández-Roblas, R; Gadea, I; García-Almeida, D; Martín-de-Hijas, NZ	1
Juan, C; Maciá, MD; Mena, A; Mulet, X; Oliver, A; Pérez, JL	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE	1
Gaillard, JL; Jackson, M; McDonnell, G; Niederweis, M; Skovierová, H; Svetlíková, Z	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Ekins, S; Williams, AJ; Xu, JJ	1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D	1
Buckle, R; Eldridge, GR; Ellis, M; Garo, E; Hu, JF; Huang, Z; Lawrence, JA; Norman, VL; Rathinavelu, S; Starks, CM; Williams, RB	1
Chang, YQ; Chen, WM; Hou, JS; Lin, J; Liu, J; Miao, ZY; Peng, LJ; Sun, PH; Zhang, XY	1
Muszynski, MJ; Rajyaguru, JM	1
Ishii, Y; Kobayashi, T; Matsumoto, T; Miyazaki, S; Tateda, K; Yamaguchi, K	1
Abbas, S; Drugeon, H; Ganiere-Monteil, C; Kergueris, MF; Le Normand, Y; Mazeas, M	1
Campbell, P; Marshall, BC; Mayer-Hamblett, N; Saiman, L	1
Adam, HJ; Laing, N; Mayer, M; Zhanel, GG	1
Amraoui, A; Bourcier, T; Cochereau, I; Delval, L; Garg, P; Goldschmidt, P; Khairallah, M; Meddeb-Ouertani, A; Pop, M; Pouliquen, P; Tandon, R; Zaghloul, K	1
Abelson, M; Bowman, L; Protzko, E; Shapiro, A	1
Duh, MS; Sacco, P; Toy, EL; Weiner, JR	1
Iglewski, BH; Wagner, VE	1
Beresniak, A; Bhagat, Y; Bingen, E; Bremond-Gignac, D; Cochereau, I; Delval, L; El Fekih, L; Goldschmidt, P; Mariani-Kurkdjian, P; Pouliquen, P	1
Amraoui, A; Bhagat, Y; Bourcier, T; Cochereau, I; Khairallah, M; Meddeb-Ouertani, A; Pop, M; Robert, PY; Zaghloul, K	1
Accurso, FJ; Harris, JK; Sagel, SD; Wagener, JS; Wagner, BD; Zemanick, ET	1
Akers, KS; Blatz, PJ; Boyer, JM; Chung, KK; Hospenthal, DR; Murray, CK; Okulicz, JF; Renz, EM	1
Acton, JD; Amin, RS; Chima, A; Ednick, M; Fenchel, MC; McPhail, GL; Seid, M; VanDyke, R; Weiland, J	1
Cockrum, P; Hammonds, WM; Meier, E; Silverstein, B; Silverstein, S; Torkildsen, GL	1
Bilderback, A; Boyle, MP; Eakin, MN; Mogayzel, PJ; Riekert, KA	1
Blavin, J; Bourcier, T; Gaucher, D; Saleh, M; Sauer, A; Speeg-Schatz, C	1
Caceres, S; Caverly, L; Fratelli, C; Kim, SH; Malcolm, K; Moskowitz, S; Nichols, DP; Nick, JA; Poch, KR; Saavedra, M; Solomon, G; Taylor-Cousar, J	1
Blanco, AR; Papa, V; Spoto, CG; Sudano Roccaro, A	1
Hayes, D; Li, X; Mansour, HM; Vogt, FG	1
Chmiel, JF; Forssén, AV; Kim, SH; Moskowitz, SM; Nichols, DP; Nick, JA; Saavedra, MT; Saiman, L; Taylor-Cousar, JL	1
Bianchi, PE; Bremond-Gignac, D; Chiambaretta, F; Delval, L; Hartani, D; Kaercher, T; Kocyla-Karczmarewicz, B; Lazreg, S; Messaoud, R; Murta, J; Nezzar, H; Renault, D; Speeg-Schatz, C; Voinea, L	1
McColley, SA	1
Bratton, DL; Burns, JL; Caceres, SM; Malcolm, KC; Moskowitz, SM; Nichols, DP; Nick, JA; Saavedra, MT; Taylor-Cousar, JL	1
Bratcher, PE; Caceres, SM; Chmiel, JF; Happoldt, CL; Malcolm, KC; Nichols, DP; Nick, JA; Saavedra, MT; Saiman, L; Taylor-Cousar, JL	1
Ausubel, FM; Gutu, AD; Hebert, W; Joseph-McCarthy, D; Koeva, M; Moskowitz, SM; O'Toole, GA; Wager, JD; Yonker, LM	1
Antony, VB; Carden, JL; Gaggar, A; Garcia, BA; Goodwin, DL; Leon, K; Rowe, SM; Smith, TA; Solomon, GM	1
Accurso, F; Albers, G; Black, P; Brown, P; Buckingham, R; Cairns, A; Davis, SD; Graff, GR; Kerby, GS; Kloster, M; Mayer-Hamblett, N; Orenstein, D; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M	1
Asbell, PA; DeCory, HH	1
Cogen, JD; Goss, CH; Nichols, DP; Nick, JA; Nick, SE; Russell, R; Saavedra, MT; Somayaji, R; Taylor-Cousar, JL	1
Klingel, M; Ratjen, F; Stanojevic, S; Tullis, E; Waters, V	1
Elgaher, WAM; Haupenthal, J; Hirsch, AKH; Lababidi, N; Ofosu Kissi, E; Rades, T; Schneider, M; Schwarz, BC; Sigal, V	1
Cogen, JD; Goss, CH; Heltshe, SL; Nichols, DP; Odem-Davis, K; Ren, CL; Skalland, M; Somayaji, R	1
Cogen, JD; Faino, AV; Gibson, RL; Hoffman, LR; Kronman, MP; Nichols, DP; Onchiri, F; Rosenfeld, M	1
de Souza Carvalho-Wodarz, C; Lababidi, N; Lehr, CM; Montefusco-Pereira, CV; Schneider, M	1
Chin, M; Somayaji, R; Thornton, C	1
Bai, F; Chen, S; Cheng, Z; Fan, Z; Jin, Y; Li, S; Liang, Y; Liu, H; Pan, X; Pletzer, D; Ren, H; Wang, P; Wu, W; Xu, C; Xu, J; Zhang, J; Zhang, Y; Zhou, J; Zhu, G	1
Baines, A; Billings, JL; Caverly, LJ; Chmiel, JF; GIbson, RL; Heltshe, SL; Kirby, S; Kong, A; Lascano, J; Mayer-Hamblett, N; Morgan, SJ; Nichols, DP; Nick, JA; Retsch-Bogart, G; Sadeghi, H; Saiman, L; Singh, PK	1
Langton Hewer, SC; Rowbotham, NJ; Smith, S; Smyth, AR; Yule, A	1
Harris, JK; Mayer-Hamblett, N; Ramsey, BW; Retsch-Bogart, G; Robertson, CE; Sagel, SD; Stevens, MJ; Wagner, BD; Zemanick, ET	1

Reviews

3 review(s) available for tobramycin and zithromax

Article	Year
Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:5 Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Health Care Costs; Humans; Patient Compliance; Quality of Life; Respiratory Tract Infections; Severity of Illness Index; Tobramycin	2008
P. aeruginosa Biofilms in CF Infection. Clinical reviews in allergy & immunology, 2008, Volume: 35, Issue:3 Topics: Animals; Azithromycin; Biofilms; Cystic Fibrosis; DNA, Bacterial; Gene Expression Regulation, Bacterial; Humans; Immunity, Mucosal; Immunocompromised Host; Lung; Opportunistic Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Tobramycin	2008
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. The Cochrane database of systematic reviews, 2023, 06-02, Volume: 6 Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Infant; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2023

Trials

12 trial(s) available for tobramycin and zithromax

Article	Year
Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American journal of respiratory and critical care medicine, 2005, Oct-15, Volume: 172, Issue:8 Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Deoxyribonuclease I; Drug Monitoring; Forced Expiratory Volume; Genotype; Heterozygote; Homozygote; Hospitalization; Humans; Pneumonia, Bacterial; Predictive Value of Tests; Proportional Hazards Models; Pseudomonas Infections; Risk Factors; Severity of Illness Index; Tobramycin; Treatment Outcome; United States	2005
3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. The British journal of ophthalmology, 2007, Volume: 91, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Conjunctivitis, Bacterial; Drug Administration Schedule; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Ophthalmic Solutions; Single-Blind Method; Tobramycin; Treatment Outcome	2007
Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Investigative ophthalmology & visual science, 2007, Volume: 48, Issue:8 Topics: Adhesives; Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Conjunctivitis, Bacterial; Female; Humans; Infant; Male; Middle Aged; Ophthalmic Solutions; Polymers; Prospective Studies; Tobramycin; Treatment Outcome; Visual Acuity	2007
Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. The Pediatric infectious disease journal, 2010, Volume: 29, Issue:3 Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Bacteria; Child; Child, Preschool; Conjunctivitis, Bacterial; Female; Humans; Infant, Newborn; Male; Ophthalmic Solutions; Tobramycin; Treatment Outcome; Young Adult	2010
[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis]. Journal francais d'ophtalmologie, 2010, Volume: 33, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Conjunctiva; Conjunctivitis, Bacterial; Edema; Erythema; Eyelid Diseases; Follow-Up Studies; Humans; Hyperemia; Infant; Infant, Newborn; Middle Aged; Ophthalmic Solutions; Safety; Single-Blind Method; Suppuration; Tobramycin; Treatment Outcome; Young Adult	2010
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Current medical research and opinion, 2011, Volume: 27, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Blepharitis; Conjunctivitis, Bacterial; Dexamethasone; Drug Combinations; Female; Humans; Instillation, Drug; Male; Middle Aged; Ophthalmic Solutions; Osmolar Concentration; Tobramycin; Treatment Outcome; Validation Studies as Topic	2011
A comparison of azithromycin and tobramycin eye drops on epithelial wound healing and tolerance after penetrating keratoplasty. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2012, Volume: 28, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Cornea; Corneal Diseases; Dexamethasone; Epithelium, Corneal; Female; Humans; Keratitis; Keratoplasty, Penetrating; Male; Middle Aged; Ophthalmic Solutions; Pain, Postoperative; Postoperative Period; Prospective Studies; Surgical Wound Infection; Tobramycin; Wound Healing; Young Adult	2012
Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Annals of the American Thoracic Society, 2014, Volume: 11, Issue:3 Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Aztreonam; Cystic Fibrosis; Drug Interactions; Female; Forced Expiratory Volume; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; Young Adult	2014
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. The British journal of ophthalmology, 2014, Volume: 98, Issue:6 Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Azithromycin; Bacteria; Child; Child, Preschool; Conjunctivitis, Bacterial; Eye Infections, Bacterial; Female; Humans; Infant; Infant, Newborn; Male; Ophthalmic Solutions; Tobramycin; Treatment Outcome	2014
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:3 Topics: Anti-Bacterial Agents; Azithromycin; Aztreonam; Cystic Fibrosis; Drug Administration Routes; Drug Interactions; Drug Monitoring; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome; Young Adult	2017
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. American journal of respiratory and critical care medicine, 2018, 11-01, Volume: 198, Issue:9 Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infant; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Time Factors; Tobramycin; Treatment Outcome	2018
Testing the effects of combining azithromycin with inhaled tobramycin for Thorax, 2022, Volume: 77, Issue:6 Topics: Administration, Inhalation; Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Forced Expiratory Volume; Humans; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2022

Other Studies

44 other study(ies) available for tobramycin and zithromax

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:1 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:8 Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA	2008
In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline; Mycobacterium; Mycobacterium Infections; Pigmentation; Species Specificity; Tigecycline	2008
Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Biofilms; Cefepime; Cephalosporins; Ciprofloxacin; Cystic Fibrosis; DNA-Binding Proteins; Humans; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; MutS DNA Mismatch-Binding Protein; Pseudomonas aeruginosa; Transcription Factors	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests	2009
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Antitubercular Agents; Disinfectants; Drug Resistance, Bacterial; Glutaral; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Mycobacterium chelonae; Mycobacterium smegmatis; o-Phthalaldehyde; Porins	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR. European journal of medicinal chemistry, 2011, Volume: 46, Issue:1 Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC. Journal of medicinal chemistry, 2017, 06-22, Volume: 60, Issue:12 Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship	2017
Optimized plant compound with potent anti-biofilm activity across gram-negative species. Bioorganic & medicinal chemistry, 2020, 03-01, Volume: 28, Issue:5 Topics: Amines; Anti-Bacterial Agents; Biofilms; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship	2020
New Journal of medicinal chemistry, 2022, 01-13, Volume: 65, Issue:1 Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Line; Cell Survival; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Pyridines; Quinolones; Quorum Sensing; Zebrafish	2022
Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds. The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:3 Topics: 1-Naphthylamine; Anti-Infective Agents; Azithromycin; Bacterial Outer Membrane Proteins; Burkholderia cepacia; Cations; Ceftazidime; Cell Membrane Permeability; Ciprofloxacin; Clarithromycin; Fleroxacin; Fluorescent Dyes; Fluoroquinolones; Gentamicins; Magnesium; Microbial Sensitivity Tests; Microscopy, Electron; Novobiocin; Oxolinic Acid; Polysaccharides, Bacterial; Tobramycin	1997
Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2000, Volume: 6, Issue:1 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Proteins; Ceftazidime; Cephalosporins; Clarithromycin; Clindamycin; Erythromycin; In Vitro Techniques; Josamycin; Microbial Sensitivity Tests; Minocycline; Ofloxacin; Oleandomycin; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Time Factors; Tobramycin	2000
[An example of simulation for a better understanding of PK/PD relationship of antibiotics]. Pathologie-biologie, 2004, Volume: 52, Issue:10 Topics: Anti-Bacterial Agents; Area Under Curve; Azithromycin; Computer Simulation; Humans; Infections; Microbial Sensitivity Tests; Tobramycin; Vancomycin	2004
Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Colistin; Dose-Response Relationship, Drug; Drug Synergism; In Vitro Techniques; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Mutation; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins; Tobramycin	2006
Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatric pulmonology, 2010, Volume: 45, Issue:6 Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Child; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sputum; Tobramycin; Young Adult	2010
Nontuberculous mycobacterium infection in a burn ICU patient. Burns : journal of the International Society for Burn Injuries, 2010, Volume: 36, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Burn Units; Burns; Cohort Studies; Fatal Outcome; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium Infections; Tobramycin; Trachea	2010
Improving evidence-based care in cystic fibrosis through quality improvement. Archives of pediatrics & adolescent medicine, 2010, Volume: 164, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Ambulatory Care; Anti-Bacterial Agents; Azithromycin; Child; Cystic Fibrosis; Deoxyribonuclease I; Evidence-Based Medicine; Guideline Adherence; Hospitals, Pediatric; Humans; Ohio; Practice Patterns, Physicians'; Quality of Health Care; Tobramycin	2010
Longitudinal association between medication adherence and lung health in people with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2011, Volume: 10, Issue:4 Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Cystic Fibrosis; Deoxyribonuclease I; Drug Prescriptions; Female; Forced Expiratory Volume; Humans; Infusions, Intravenous; Longitudinal Studies; Male; Medication Adherence; Outcome Assessment, Health Care; Pharmacy; Retrospective Studies; Tobramycin; Young Adult	2011
Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. The Journal of surgical research, 2013, Volume: 183, Issue:2 Topics: Animals; Anti-Bacterial Agents; Azithromycin; Burns; Ciprofloxacin; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Wound Infection	2013
Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy. Current eye research, 2013, Volume: 38, Issue:8 Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chloramphenicol; Drug Resistance; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Netilmicin; Quinolines; Staphylococcus epidermidis; Tobramycin; Vancomycin	2013
Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2014, Feb-14, Volume: 52 Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Azithromycin; Drug Compounding; Dry Powder Inhalers; Methanol; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Powder Diffraction; Powders; Solutions; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; Tobramycin; X-Ray Diffraction	2014
Practice guidelines, clinical trials, and unexpected results in cystic fibrosis. Annals of the American Thoracic Society, 2014, Volume: 11, Issue:3 Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2014
Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11 Topics: Anti-Bacterial Agents; Azithromycin; Biofilms; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Metalloproteases; Microbial Sensitivity Tests; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Sputum; Tobramycin; Virulence Factors	2014
An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12 Topics: Anti-Bacterial Agents; Azithromycin; Biofilms; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Therapy, Combination; Fumarates; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin	2017
Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients. BMC pulmonary medicine, 2018, Feb-14, Volume: 18, Issue:1 Topics: Administration, Inhalation; Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Burkholderia cepacia complex; Burkholderia Infections; Ceftazidime; Clinical Protocols; Cohort Studies; Consolidation Chemotherapy; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult	2018
Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. PloS one, 2018, Volume: 13, Issue:10 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Ciprofloxacin; Conjunctiva; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Female; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Male; Methicillin; Microbial Sensitivity Tests; Middle Aged; Oxacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus pneumoniae; Tobramycin; Trimethoprim; United States	2018
Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Annals of the American Thoracic Society, 2019, Volume: 16, Issue:7 Topics: Administration, Inhalation; Administration, Intravenous; Adult; Anti-Bacterial Agents; Azithromycin; Colistin; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Logistic Models; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Young Adult	2019
Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2019, Volume: 16, Issue:7 Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Logistic Models; Male; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2019
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis. Journal of controlled release : official journal of the Controlled Release Society, 2019, 11-28, Volume: 314 Topics: Acetylcysteine; Administration, Inhalation; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Ciprofloxacin; Cystic Fibrosis; Drug Stability; Drug Storage; Expectorants; Horses; Mucus; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2019
Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. American journal of respiratory and critical care medicine, 2020, 02-15, Volume: 201, Issue:4 Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Aztreonam; Child; Cohort Studies; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Retrospective Studies; Tobramycin; Young Adult	2020
Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Annals of the American Thoracic Society, 2021, Volume: 18, Issue:2 Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Child; Cystic Fibrosis; Humans; Retrospective Studies; Tobramycin; Young Adult	2021
Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2020, Volume: 157 Topics: Acetylcysteine; Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Ciprofloxacin; Curcumin; Cytokines; Drug Carriers; Drug Combinations; Drug Compounding; Expectorants; Freeze Drying; Humans; Inflammation Mediators; Macrophages; Microbial Viability; Mucus; Nanoparticles; Permeability; Polylactic Acid-Polyglycolic Acid Copolymer; Pseudomonas aeruginosa; Pseudomonas Infections; THP-1 Cells; Tobramycin	2020
Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More? Annals of the American Thoracic Society, 2021, Volume: 18, Issue:2 Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Humans; Pseudomonas Infections; Tobramycin	2021
Synergistic bactericidal activities of tobramycin with ciprofloxacin and azithromycin against Klebsiella pneumoniae. The Journal of antibiotics, 2021, Volume: 74, Issue:8 Topics: Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Ciprofloxacin; Codon; Dogs; Drug Resistance, Microbial; Drug Synergism; Humans; Klebsiella Infections; Klebsiella pneumoniae; Luminescent Proteins; Microbial Sensitivity Tests; Red Fluorescent Protein; Tobramycin	2021
Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection. BMC microbiology, 2023, 10-27, Volume: 23, Issue:1 Topics: Administration, Inhalation; Anti-Bacterial Agents; Azithromycin; Bacteria; Child; Cystic Fibrosis; Humans; Microbiota; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2023